The financials
Lexicon Pharmaceuticals, Inc. by the numbers
Lexicon Pharmaceuticals, Inc. (LXRX) reported revenue of $21M in Q1 2026 (quarter ended March 31, 2026), up 1572% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $1.0M. For the full year FY2025, revenue was $50M (+60% year on year) and net income −$50M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $21M | $1.3M | +1572% |
| Gross profit | $21M | $1.2M | +1604% |
| Operating income | −$996K | −$26M | n/a |
| Net income | −$1.0M | −$25M | n/a |
| Diluted EPS | $0.00 | −$0.07 | to a profit |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $20.0M (+52%)
Segment Latestquarter on quarteryear on year
- License$20.0M$20.0MQoQ +52%year on year -+52%-
Biotechnology
The closest names by size in the same industry